Alnylam Pharmaceuticals Press Release _ Jan 07, 2021 _ Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyl · 3 pages
Preview the first 2 pages of this press release
Create a free account to start reading
Full documents are included with Professional
Earnings release
19 pages
Annual report
Form 10-K · 139 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (16)
177 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (13)
21 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (17)
20 pages
Presentation
Alnylam Pharmaceuticals Inc. Q4 2020 Earnings Call Feb 11 2021
33 pages
Presentation
Alnylam Pharmaceuticals Inc. - Special Call (15)
116 pages
Press release
Alnylam Pharmaceuticals Press Release _ Nov 24, 2020 _ Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO⢠(lumasiran), the First and Onl
4 pages
Press release
Alnylam Pharmaceuticals Press Release _ Jan 07, 2021 _ Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyl
3 pages